Ulrika Ludvigsson
Ulrika Ludvigsson has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Gunilla Olmedal
Evidensia Specialist Animal Hospital, Helsingborg, Sweden
3 shared publications- Linda Toresson
Evidensia Specialist Animal Hospital Helsingborg, 254 66 Helsingborg, Sweden
3 shared publications - Amanda B. Blake
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, TX 77843, USA
2 shared publications - Jan S. Suchodolski
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
2 shared publications Josefin Hellgren
Evidensia Specialist Animal Hospital, Helsingborg, Sweden
2 shared publicationsMichaela Toni
Evidensia Specialist Animal Hospital, Helsingborg, Sweden
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (7) , 857-866
Dogs with chronic enteropathy and low disease activity show signs consistent with compromised emotional health compared to matched healthy control dogs
Objective: To compare emotional health in dogs with chronic enteropathy (CE) and healthy controls. Methods: 50 dogs with CE and matched healthy dogs were enrolled in a cross-sectional, case-control, questionnaire-based study from June 2022 to August 2023. Gastrointestinal disease activity was assessed with the Canine Inflammatory Bowel Disease Activity Index and fecal score. Emotional health was assessed with the Positive and Negative Activation Scale and questions regarding behaviors associated with emotional arousal and signs of distress in specific situations. Results: Dogs with CE had significantly higher mean negative activation scores (0.48 vs 0.33; Cohen’s d = 1.21), on a scale ranging from 0.2 (minimal contribution of negative affective systems) to 1.0 (maximal contribution). Frequency of displacement behaviors and signs of distress were graded on a 5-point Likert scale (1 [no signs] to 5 [frequent behaviors or obvious signs of distress]). Scores ≥ 3 were considered clinically relevant. Dogs with CE had a score of ≥ 3 more often than healthy dogs for displacement behaviors in 5 of 7 situations (relative risk range, 3.19 to 13.64; all 95% CIs excluded 1) and were more likely to score ≥ 3 for signs of distress when owners prepared to leave the house (relative risk, 1.92; 95% CI, 1.14 to 3.35). Conclusions: These results indicated a relationship between CE and signs consistent with compromised emotional health. Clinical Relevance: The findings suggest that a veterinary approach integrating physical and emotional dimensions of health may be of importance. Further studies are warranted to explore whether emotional interventions may influence gastrointestinal outcomes.
- 1 July 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (7) , 857-866
Open AccessDogs with chronic enteropathy and low disease activity show signs consistent with compromised emotional health compared to matched healthy control dogs
Objective: To compare emotional health in dogs with chronic enteropathy (CE) and healthy controls. Methods: 50 dogs with CE and matched healthy dogs were enrolled in a cross-sectional, case-control, questionnaire-based study from June 2022 to August 2023. Gastrointestinal disease activity was assessed with the Canine Inflammatory Bowel Disease Activity Index and fecal score. Emotional health was assessed with the Positive and Negative Activation Scale and questions regarding behaviors associated with emotional arousal and signs of distress in specific situations. Results: Dogs with CE had significantly higher mean negative activation scores (0.48 vs 0.33; Cohen’s d = 1.21), on a scale ranging from 0.2 (minimal contribution of negative affective systems) to 1.0 (maximal contribution). Frequency of displacement behaviors and signs of distress were graded on a 5-point Likert scale (1 [no signs] to 5 [frequent behaviors or obvious signs of distress]). Scores ≥ 3 were considered clinically relevant. Dogs with CE had a score of ≥ 3 more often than healthy dogs for displacement behaviors in 5 of 7 situations (relative risk range, 3.19 to 13.64; all 95% CIs excluded 1) and were more likely to score ≥ 3 for signs of distress when owners prepared to leave the house (relative risk, 1.92; 95% CI, 1.14 to 3.35). Conclusions: These results indicated a relationship between CE and signs consistent with compromised emotional health. Clinical Relevance: The findings suggest that a veterinary approach integrating physical and emotional dimensions of health may be of importance. Further studies are warranted to explore whether emotional interventions may influence gastrointestinal outcomes.
- Open Access
- 1 May 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (5) , 571-580
Repeated fecal microbiota transplantation in dogs with chronic enteropathy can decrease disease activity and corticosteroid usage
Objective: Evaluate clinical and fecal parameters in dogs with refractory chronic enteropathy (CE) treated with repeated fecal microbiota transplantation (FMT) as adjunct treatment. Methods: This was a prospective longitudinal observational study from September 25, 2021, to June 20, 2024. Thirty-nine dogs received 2 to 3 rectal FMTs over 1 month. Canine inflammatory bowel disease activity index (CIBDAI) and fecal samples were assessed for 6 months. Fecal samples were analyzed for dysbiosis index, bile acids, and calprotectin. Results: 28 of 39 dogs responded to FMT. Eight dogs had a short-lasting response. Before FMT, baseline CIBDAI was equivalent in responders and nonresponders. Responders had a significantly decreased CIBDAI at 1 month, which remained unaltered at 6 months in long-lasting responders (LLRs). Baseline dysbiosis index (mean [95% CI]) was significantly lower in LLRs (–0.02 [–3.3 to 2.7]) versus nonresponders and short-lasting responders combined (N/SRs; 2.9 [–0.2 to 6.0]). Baseline percentage of secondary unconjugated fecal bile acids was higher in LLRs (65 [41 to 89]) versus N/SRs (30 [6 to 54]). Dysbiosis index decreased significantly at the time point for the third FMT in LLRs (–2.4 [–3.9 to 2.2]) but not in N/SRs (3.3 [–0.4 to 5.7]). Corticosteroid tapering was achieved in 13 responders. Mild adverse events were noted in 4 dogs. Conclusions: This repeated FMT protocol was an effective adjunct treatment in refractory CE dogs, especially in dogs with no or mild dysbiosis. Marked dysbiosis and BA dysmetabolism before and after FMT appeared associated with no clinical response or a short-lasting response to FMT, potentially requiring repeated FMT. Clinical Relevance: Repeated FMT could reduce disease activity and corticosteroid usage in dogs with refractory CE.
- 1 May 2026
- Published by American Veterinary Medical Association (AVMA) in Journal of the American Veterinary Medical Association
- Vol. 264 (5) , 571-580
Open AccessRepeated fecal microbiota transplantation in dogs with chronic enteropathy can decrease disease activity and corticosteroid usage
Objective: Evaluate clinical and fecal parameters in dogs with refractory chronic enteropathy (CE) treated with repeated fecal microbiota transplantation (FMT) as adjunct treatment. Methods: This was a prospective longitudinal observational study from September 25, 2021, to June 20, 2024. Thirty-nine dogs received 2 to 3 rectal FMTs over 1 month. Canine inflammatory bowel disease activity index (CIBDAI) and fecal samples were assessed for 6 months. Fecal samples were analyzed for dysbiosis index, bile acids, and calprotectin. Results: 28 of 39 dogs responded to FMT. Eight dogs had a short-lasting response. Before FMT, baseline CIBDAI was equivalent in responders and nonresponders. Responders had a significantly decreased CIBDAI at 1 month, which remained unaltered at 6 months in long-lasting responders (LLRs). Baseline dysbiosis index (mean [95% CI]) was significantly lower in LLRs (–0.02 [–3.3 to 2.7]) versus nonresponders and short-lasting responders combined (N/SRs; 2.9 [–0.2 to 6.0]). Baseline percentage of secondary unconjugated fecal bile acids was higher in LLRs (65 [41 to 89]) versus N/SRs (30 [6 to 54]). Dysbiosis index decreased significantly at the time point for the third FMT in LLRs (–2.4 [–3.9 to 2.2]) but not in N/SRs (3.3 [–0.4 to 5.7]). Corticosteroid tapering was achieved in 13 responders. Mild adverse events were noted in 4 dogs. Conclusions: This repeated FMT protocol was an effective adjunct treatment in refractory CE dogs, especially in dogs with no or mild dysbiosis. Marked dysbiosis and BA dysmetabolism before and after FMT appeared associated with no clinical response or a short-lasting response to FMT, potentially requiring repeated FMT. Clinical Relevance: Repeated FMT could reduce disease activity and corticosteroid usage in dogs with refractory CE.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (5) , e70206
Fecal and Clinical Profiles of Dogs With Chronic Enteropathies Treated With Bile Acid Sequestrants for 5–47 Months: A Retrospective Case Series
Background: Bile acid (BA) malabsorption and BA diarrhea (BAD) are prevalent but underdiagnosed conditions in people with chronic diarrhea of multiple causes. Recent studies have shown BA dysmetabolism in dogs with chronic enteropathies (CE). Objective: Describe canine inflammatory bowel disease activity index (CIBDAI), dysbiosis index (DI) and fecal BA concentrations in healthy dogs and dogs with refractory or partially immunosuppressive-responsive CE or CE dogs requiring high doses of corticosteroids, treated with BA sequestrants (BAS). Animals: Twenty-four CE dogs and 18 healthy dogs. Methods: Retrospective case series. Dogs with CE were treated with BAS as adjunctive treatment. Fecal BA was analyzed using liquid chromatography–tandem mass spectrometry. Fecal microbiota was assessed using DI. Response to treatment was defined as a decrease in CIBDAI category. Results: Sixteen of 24 dogs improved clinically after BAS treatment (cholestyramine, 44–133 mg/kg q12h; colesevelam, 7–24 mg/kg q12h; colestipole, 26 mg/kg q24h). Duration of treatment was 5–47 months. Median (range) CIBDAI decreased from 6.5 (4–13) to 3 (2–5) in responders. At baseline, responders had a higher median (range) percentage of fecal unconjugated primary BAs (93 [1–100]) versus non-responders (2.5 [0–95]) and healthy dogs (1.5 [0–19]). Dysbiosis index (median [range]) was higher in responders (4.2 [−4.7 to 9.0]) versus non-responders (−0.1 [−1.5 to 5.7]) and healthy dogs (−4.5 [−6.4 to −0.2]). Conclusions and Clinical Importance: Treatment with BAS as adjunctive treatment potentially may benefit some dogs with nonresponsive or partially immunosuppressive-responsive enteropathy or CE dogs requiring high doses of corticosteroids.
- 1 September 2025
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 39 (5) , e70206
Open AccessFecal and Clinical Profiles of Dogs With Chronic Enteropathies Treated With Bile Acid Sequestrants for 5–47 Months: A Retrospective Case Series
Background: Bile acid (BA) malabsorption and BA diarrhea (BAD) are prevalent but underdiagnosed conditions in people with chronic diarrhea of multiple causes. Recent studies have shown BA dysmetabolism in dogs with chronic enteropathies (CE). Objective: Describe canine inflammatory bowel disease activity index (CIBDAI), dysbiosis index (DI) and fecal BA concentrations in healthy dogs and dogs with refractory or partially immunosuppressive-responsive CE or CE dogs requiring high doses of corticosteroids, treated with BA sequestrants (BAS). Animals: Twenty-four CE dogs and 18 healthy dogs. Methods: Retrospective case series. Dogs with CE were treated with BAS as adjunctive treatment. Fecal BA was analyzed using liquid chromatography–tandem mass spectrometry. Fecal microbiota was assessed using DI. Response to treatment was defined as a decrease in CIBDAI category. Results: Sixteen of 24 dogs improved clinically after BAS treatment (cholestyramine, 44–133 mg/kg q12h; colesevelam, 7–24 mg/kg q12h; colestipole, 26 mg/kg q24h). Duration of treatment was 5–47 months. Median (range) CIBDAI decreased from 6.5 (4–13) to 3 (2–5) in responders. At baseline, responders had a higher median (range) percentage of fecal unconjugated primary BAs (93 [1–100]) versus non-responders (2.5 [0–95]) and healthy dogs (1.5 [0–19]). Dysbiosis index (median [range]) was higher in responders (4.2 [−4.7 to 9.0]) versus non-responders (−0.1 [−1.5 to 5.7]) and healthy dogs (−4.5 [−6.4 to −0.2]). Conclusions and Clinical Importance: Treatment with BAS as adjunctive treatment potentially may benefit some dogs with nonresponsive or partially immunosuppressive-responsive enteropathy or CE dogs requiring high doses of corticosteroids.